Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 8/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116202 | 0.98 | KDM4E (0.51) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL28475063 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL13280597 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL11156433 | 0.84 | KDM4E (0.60) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL24104384 | 0.84 | GAA (0.56) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL25213358 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL1005468 | 0.84 | HPGD (0.53) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL1734942 | 0.84 | KDM4E (0.51) | KDM4EPOLBGAACYP1A2CYP2D6 | |
| SCHEMBL536121 | 0.83 | SMN1; SMN2 (0.46) | KDM4EPOLBGAAALDH1A1HPGD | |
| SCHEMBL1559038 | 0.82 | KDM4E (0.50) | KDM4EPOLBGAACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246108-A1 | Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative | TOKUYAMA CORPORATION (JP) | 2021-08-12 | — | — | US | disclosed |
| EP-3816151-A1 | METHOD FOR PRODUCING ?-AZIDOANILINE DERIVATIVE OR ?, ?'-DIAZIDE DERIVATIVE | Tokuyama Corporation (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| CN-104030987-A | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA | 2014-09-10 | — | — | CN | disclosed |
| CN-102574786-A | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO SA | 2012-07-11 | — | — | CN | disclosed |
| EP-2414328-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2012-02-02 | — | — | US | disclosed |
| EP-2281819-A1 | Benzimidazolyl or benzoxazolyl derivatives | Novartis AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-20090298824-A1 | Organic compounds | PRESS NEIL J | 2009-12-03 | — | — | US | disclosed |
| EP-1709015-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070906-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028959-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, FH, DPYD | KDM4E 806/4885POLB 517/4885GAA 318/4885 |
| US-20210246108-A1 | Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative | QDPR, AZI2, NISCH | KDM4E 4043/4885POLB 843/4885GAA 785/4885 |
| US-20090298824-A1 | Organic compounds | CXCR2, CXCR3, CXCR1 | KDM4E 4128/4885POLB 3284/4885GAA 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.